Isomorphic Labs secures $5 billion to move drug candidates forward

Isomorphic Labs has raised $5 billion, its second billion-dollar round in six months, to develop its drug-design platform and advance its pipeline toward clinical trials. The company says IsoDDE aims to improve predictions about how drugs bind to targets, but it has no approved drug yet.

WTF Index NEUTRAL
◄ Terminator 0 Idiocracy 0 ►

The funding and drug discovery update describes potential medical benefits but reports no clinical success or clear societal harm.

Isomorphic Labs secures $5 billion to move drug candidates forward

Isomorphic Labs has raised $5 billion to develop its AI-based drug discovery work and move its drug pipeline closer to clinical trials. The financing is the Alphabet company’s second billion-dollar round in six months, following a $2.1 billion raise in May 2026.

New funding backs the company’s drug development plans

Greenoaks and Sequoia Capital co-led the round. Andreessen Horowitz joined as a new backer, alongside Alphabet and all existing investors.

Isomorphic Labs plans to put the money toward its in-house platform, IsoDDE, and toward advancing its drug pipeline. The stated goal of moving candidates toward clinical trials marks a step in the company’s effort to turn computational drug design into treatments that can be tested in people.

The size of the raise signals substantial investor backing for that effort. It does not, by itself, show that a drug candidate has succeeded in clinical testing or that a treatment is ready for patients. Isomorphic Labs has no approved drug to show for its work yet.

IsoDDE targets a challenge in drug design

IsoDDE stands for Isomorphic Drug Design Engine. According to the company, it goes beyond AlphaFold 3 and aims to better predict drug binding and docking sites.

In plain terms, those predictions concern how a potential drug may fit and interact with a biological target. Better predictions could help guide the search for drug candidates, though the source does not report a clinical result or an approved medicine from the platform.

The company’s approach centers on building its own tools while developing its pipeline. The new funding is intended to support both parts of that work: improving the platform and taking drug candidates toward clinical trials.

Partnerships and leadership

Isomorphic Labs works with Novartis, Eli Lilly, and Johnson & Johnson. Those collaborations place the company’s drug discovery work alongside established pharmaceutical companies, while the company continues to develop its own pipeline.

Demis Hassabis leads Isomorphic Labs. He stepped down from day-to-day leadership of Google Deepmind in August 2026 and now serves as Alphabet’s Chief Scientist. Hassabis won the 2024 Nobel Prize in Chemistry alongside John Jumper for their work on AlphaFold.

That background connects Isomorphic Labs to research associated with protein structure prediction, while its stated platform goals focus on drug binding and docking. The company’s next milestone, as described in the source, is advancing its pipeline toward clinical trials.

AlphaFold research moves into a new phase

Deepmind’s original AlphaFold team was disbanded in July 2026. Many researchers moved to Isomorphic Labs or were reassigned to other projects, and nearly a quarter left Deepmind entirely.

Deepmind continued to release work in the area. In early November 2026, it shipped AlphaGenome 2, which predicts how DNA variants affect gene activity in specific cell types.

Together, these developments show research and staff moving across different projects connected to biology and AI. Isomorphic Labs is using its new financing to push its own drug design platform and pipeline forward, but the key test remains whether that work can produce candidates that progress through clinical trials.